Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 10 trades.
Regeneron stock rose early Tuesday on a strong fourth-quarter report that included in-line sales of eye drug Eylea.
Clearly, options traders are pricing in a big move for Regeneron Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Regeneron Pharmaceuticals is a Zacks Rank ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback